Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.
